Summary of the analysis of differences between immune blood cell values for patients with multiple myeloma at presentation and over the 2-year treatment course of the Eastern Cooperative Oncology Group protocol
| Cell type . | Median* . | P value . |
|---|---|---|
| Total white cell count | − 1750 | < .0001 |
| Total lymphocytes | − 845 | < .0001 |
| CD2 | − 305 | < .0001 |
| CD4 | − 274 | < .0001 |
| CD8 | − 75 | < .0001 |
| CD16 | − 34 | .0042 |
| CD19 | − 103 | < .0001 |
| CD2+/HLADR+ | 19 | .4163 |
| Naive CD4 | − 78 | < .0001 |
| Activated CD4 | − 103 | < .0001 |
| CD3 | − 414 | < .0001 |
| Cell type . | Median* . | P value . |
|---|---|---|
| Total white cell count | − 1750 | < .0001 |
| Total lymphocytes | − 845 | < .0001 |
| CD2 | − 305 | < .0001 |
| CD4 | − 274 | < .0001 |
| CD8 | − 75 | < .0001 |
| CD16 | − 34 | .0042 |
| CD19 | − 103 | < .0001 |
| CD2+/HLADR+ | 19 | .4163 |
| Naive CD4 | − 78 | < .0001 |
| Activated CD4 | − 103 | < .0001 |
| CD3 | − 414 | < .0001 |